Top Biotech Stocks to Watch: By Iqra Jamal

Top Biotech Stocks to Watch: Research Article by Iqra Jamal

Biotech industries manufacture a broad range of health therapies, vaccines, medicines, drugs, and pharmaceutical products to treat the illness. The Covid-19 insurgency has increased the demand for vaccines causing the stock market’s earnings and popularity to boost at the highest rate. However, the biotech stocks have endured ebbs and flows throughout the years.
Pharmaceutical products take a lot of time and cost. And all the efforts can go waste if FDA doesn’t approve drugs or therapy.

The biotech industry reported total market size revenue of $298.7bn for the year 2021. Growing demand for vaccines and drugs, improving the healthcare structure in underdeveloped areas, and growing R&D costs for advancement in biotechnology will accelerate the revenue size. It’s anticipated to enlarge at a CAGR of 15.83℅ from 2021 to 2028. The profitable government strategies, the launch of advanced products, and the robust investment in the biotechnology sector are some of the market driving factors.

The anxiety of current delta variant coronavirus has attracted attention to biotech stocks all around the world. While the other stock markets are facing weak growth, the biotech stocks are growing to become a top market. The top four biotech stocks to watch in July 2021 are listed as Moderna Inc (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX), Johnson & Johnson (NYSE:JNJ), and Khmer Therapeutics Inc (NASDAQ: KYMR).

1. Moderna Inc

Moderna is one of the finest biotech stocks to develop Covid-19 vaccines. The company engages in transformative drugs founded on messenger ribonucleic acid (mRNA). It applies mRNA science to curtail the unwanted activation of the human immune system.

Due to the Covid-19 upheaval, the company’s stock has risen over 50℅ in the last few months. Earlier this month, the government of Argentina has signed a contract to supply 20 million doses of Moderna’s Covid vaccine. The vaccine is still in high demand due to the uprising of lethal delta variant cases. The company has achieved an outstanding revenue of $1.94 billion this year, compared to $8.4 million the previous year. Meanwhile, its net worth is $1.22 billion.

2. Khmer Therapeutics Inc

This is a biopharmaceutical company headquartered in Massachusetts. Over the past few months, the stock has been showing favorable signs of about 15℅ market gains. The company has disclosed the current data revealing the capacity of its STAT3 degraders for the treatment of Peripheral T-cell Lymphoma. The figures have shown that its STAT3 degraders can achieve above 90℅ degradations of mutants. Also, work in down-regulation of STAT3 dependent genes and antitumor activity across Tcell and T-cell subtypes.

3. BioNTech SE

Like Moderna, BioNTech has overwhelmed this year with a 31% uprising of stock since July. It works in collaboration with Pfizer to deliver a handful amount of popular vaccines in the market. The vaccine’s expected to raise revenue by $26 billion this year. Booster shots can work well to cure the sickness along with enlarging the company’s profit.

BioNTech has announced that it will work on malaria vaccines with clinical trials start by the end of 2022. Moreover, it has signed a contract with the United States to supply 200 million doses by the spring of 2022. The recent reports are revealing delays in the manufacturing process of the Moderna vaccine due to some laboratory testing issues. However, Moderna can be the top biotech stock as the demand for delta variant vaccines has risen to the height amidst the Covid-19 insurgency.

Similarly, other stocks like Kymera Therapeutics Inc and BioNTch SE are at the highest peak these days. Although, Covid-19 stimulated the growth of the biotech industry. Yet, ups and downs are part of this industry.